Medicinal Chemistry of New Compounds to Treat Tuberculosis
Marina Candido Primi, Natanael Dante Segretti and Elizabeth Igne Ferreira
Affiliation: Laboratory of Design and Synthesis of Chemotherapeutic Potentially Active against Neglected Diseases, Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo – FCF/USP Av. Prof. Lineu Prestes, 580 05508-900 Sao Paulo-SP, Brazil.
Keywords: Anti-TB pipelines, designing anti-TB drug candidates, LAPEN contribution, natural products, new anti-TB
candidates, new anti-TB leads, tuberculosis.
Tuberculosis (TB), a 19th century disease, is still present in the beginning of the Third
Millennium. It has been considered pandemic, since around two billion people are infected with M.
tuberculosis. Multi-drug resistant TB has been the biggest challenge for chemotherapy. In order to face
this severe health problem, many institutions, private and public ones, have been investing in the
search for new and better drug candidates. The pipeline of potential anti-TB drugs presents new
molecules and formulations that have been submitted to pre-clinical and clinical assays. Medicinal Chemistry has an
important role towards the objective of finding new leads through classic and modern processes. This paper reviews some
aspects of this search, emphasizing the features of the main compounds under investigation and those that are in
preliminary and final clinical trials and includes the contribution of our laboratory (LAPEN) in the area of designing new
anti-TB drug candidates.
Rights & PermissionsPrintExport